Of 43 isolates of methicillin-resistant Staphylococcus aureus, 90% were inhibited by 8 ,ug or less of N-formimidoyl thienamycin per ml by the agar-dilution technique. Cefamandole, cefotaxime, cefoperazone, moxalactam, and cefsulodin showed relatively poor activity. Vancomycin was the most active compound by weight, inhibiting 93% of strains at 1 ,ug/ml. Third-generation cephalosporins, including cefoperazone, cefotaxime, and cefsulodin, are generally less active than cephalothin against staphylococci and other gram-positive organisms (12). Moxalactam, a 1-oxa cephalosporin, resembles these compounds in its spectrum of activity (12). Recently a unique P-lactam, Nformimidoyl thienamycin (MK0787) has been shown to be very active against facultative gram-positive cocci. The minimum inhibitory concentration of N-formimidoyl thienamycin against over 350 methicillin-susceptible S. aureus isolates was less than 1.0 pLg/ml, with at least 90%o of the strains in five studies inhibited by 0.125 ,ug/ml (6, 9, 10, 15, 16). The purpose of this study was to compare and contrast the in vitro activity of the compounds against MRSA strains isolated from patients at a university medical center.
Of 43 isolates of methicillin-resistant Staphylococcus aureus, 90% were inhibited by 8 ,ug or less of N-formimidoyl thienamycin per ml by the agar-dilution technique. Cefamandole, cefotaxime, cefoperazone, moxalactam, and cefsulodin showed relatively poor activity. Vancomycin was the most active compound by weight, inhibiting 93% of strains at 1 ,ug/ml.
Strains of Staphylococcus aureus exhibiting intrinsic resistance to penicillinase-resistant penicillins have been recognized since the introduction of methicillin 20 years ago (7) . In many European hospitals, the strains became established as prevalent nosocomial pathogens during the 1960s, accounting for 30 to 50% of the S. aureus isolates in some centers (8) Third-generation cephalosporins, including cefoperazone, cefotaxime, and cefsulodin, are generally less active than cephalothin against staphylococci and other gram-positive organisms (12) . Moxalactam, a 1-oxa cephalosporin, resembles these compounds in its spectrum of activity (12) . Recently a unique P-lactam, N- formimidoyl thienamycin (MK0787) has been shown to be very active against facultative gram-positive cocci. The minimum inhibitory concentration of N-formimidoyl thienamycin against over 350 methicillin-susceptible S. aureus isolates was less than 1.0 pLg/ml, with at least 90%o of the strains in five studies inhibited by 0.125 ,ug/ml (6, 9, 10, 15, 16 colony-forming units. The Mueller Hinton agar plates were prepared with stock solutions of each antibiotic made on the day of use to yield twofold serial dilutions ranging from 32 to 0.125 ,ug/ml. After incubation at 35°C for 18 h, the minimum inhibitory concentration was interpreted as the lowest concentration of antibiotic which permitted no visible growth. The in vitro activities of the newer ,-lactam compounds (N-formimidoyl thienamycin, moxalactam, cefaperazone, cefsulodin, and cefotaxime) against MRSA were compared with those for nafcillin, cefamandole, and vancomycin (Fig.   1) . Vancomycin was the most active by weight, inhibiting more than 90%o of the strains at 1 ,ug/ ml. N-formimidoyl thienamycin inhibited 50% of the isolates at 2 ,ug/ml and 90% at 8 ,ug/ml. All other compounds failed to demonstrate activity against these strains.
There have been marked temperature and inoculum effects demonstrated in some in vitro studies of the activity of cephalosporins against strains of MRSA (3, 11) . Although other investigators have not shown these effects (14) , it seems prudent to interpret in vitro data on the activity of newer cephalosporins and other 3-lactam antibiotics with caution. Furthermore, there is a marked difference in the in vitro susceptibility of methicillin-susceptible versus methicillin-resistant strains of S. aureus for Nformimidoyl thienamycin, suggesting a parallel resistance which may also have relevance with regard to its in vivo activity.
The in vitro activity of N-formimidoyl thienamycin against MRSA has been previously reported in only 12 isolates. N-formimidoyl thienamycin inhibited 90%o of the 11 isolates studied by Verbist and Verhaegen at 1 ,ug/ml (16) and 1 isolate reported by Kropp et al. at 20 ,ug/ml (10 
